<DOC>
	<DOC>NCT02748837</DOC>
	<brief_summary>This is the open label, multicenter Phase 1 study which consists of a dose escalation to determine the maximum tolerated dose (MTD) and cohort expansion to obtain a preliminary evaluation of anti-tumor activity. ERY974 is intravenously injected to patients with Glypican 3 positive advanced solid tumors until unacceptable toxicity or disease progression.</brief_summary>
	<brief_title>A Study of ERY974 in Patient With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Male or female patient with Glypican 3 positive advanced solid tumor not amenable to standard therapy or for which standard therapy is not available or not indicated Measurable tumor Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 Adequate bone marrow, liver, and renal function Adequate coagulation status Patients with more than a single brain metastasis ( &gt;1 cm) Patients with acute or chronic infection Major surgery within 28 days Pregnant or lactating women Patients with interstitial pneumonitis Patients require regular ascites/pleural effusion drainage</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>